Reviewer's report

Title: Efficacy and safety of treatments for macular oedema secondary to retinal vein occlusion: a systematic review

Version: 2 Date: 7 August 2013

Reviewer: Winfried W Amoaku

Reviewer's report:

Mechanisms of action of ranibizumab (anti-VEGF) is well described. However, the other actions (mechanisms) of dexamethasone need to be clearly stated rather than a bland statement eg on Pg 5-6 that it is anti-inflammatory. Specifically, the effects on other cytokines eg IL-6, IL-8, ICAM-1 and MCP-1, some of which are elevated in RVO should stated. This is especially as the anti-VEGF effect of dexamethasone is limited. Mechanisms of triamcinolone need to be mentioned as well.

The referencing needs to be improved. Eg.
On Pg 9, 2nd para: cite BRAVO
Pg 9,3rd Para: Insert ref for ROCC
Last para: ditto
Pg 14 1st para: reference in text

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have received educational travel grants from Allergan, Alcon, Bayer, Novartis and Pfizer, and served as a consultant to Alcon, Alimera, Allergan, Bayer, Novartis and Pfizer.

My institution has received research grants from Allergan and Novartis.